程序性死亡受体1抑制剂单药治疗复发难治非霍奇金淋巴瘤临床观察

Clinical observation of programmed death receptor 1 inhibitor alone in treatment of relapsed/refractory non⁃Hodgkin lymphoma

目的探讨程序性死亡受体1(PD⁃1)抑制剂治疗复发难治非霍奇金淋巴瘤的临床效果及不良反应。方法回顾性分析2018年7月至2021年12月临沂市肿瘤医院收治的31例接受PD⁃1抑制剂单药治疗的复发难治非霍奇金淋巴瘤患者的临床资料,分析患者临床疗效及不良反应。结果31例患者接受PD⁃1抑制剂单药治疗3~4个周期后,部分缓解13例,疾病稳定3例,疾病进展15例,客观缓解率为41.9%(13/31),疾病控制率为51.6%(16/31);外周T细胞淋巴瘤患者客观缓解率为42.9%(9/21),疾病控制率为57.1%(12/21)。截至2022年7月30日随访结束,中位无进展生存时间为8个月(95%CI 1.6~14.4个月),中位总生存时间为15个月(95%CI 5.7~24.3个月)。全组不良反应发生率为67.7%(21/31),其中1~2级20例,3~4级1例。结论PD⁃1抑制剂治疗复发难治非霍奇金淋巴瘤有一定疗效,总体药物不良反应发生率较高,但在可控范围内。

Objective To investigate the clinical efficacy and side effects of programmed death receptor 1(PD⁃1)inhibitor in the treatment of relapsed/refractory non⁃Hodgkin's lymphoma(NHL).Methods The clinical data of 31 patients with relapsed/refractory NHL treated with PD⁃1 inhibitor alone in Linyi Cancer Hospital from July 2018 to December 2021 were retrospectively analyzed.The clinical efficacy and adverse reactions were also analyzed.Results After 3-4 cycles of PD⁃1 inhibitor treatment alone,13 cases achieved partial remission,3 cases achieved stable disease and 15 cases had the progression of disease.The objective remission rate was 41.9%(13/31),and the disease control rate was 51.6%(16/31).The objective remission rate of patients with peripheral T⁃cell lymphoma was 42.9%(9/21),and the disease control rate was 57.1%(12/21).By the end of follow⁃up in July 30,2022,the median progression⁃free survival time was 8 months(95%CI 1.6-14.4 months)and the median overall survival time was 15 months(95%CI 5.7-24.3 months).The incidence of adverse reactions in the whole group was 67.7%(21/31),of which grade 1-2 occurred in 20 cases,and grade 3-4 occurred in 1 case.Conclusions PD⁃1 inhibitor has a certain effect in the treatment of relapsed/refractory NHL;the overall incidence of adverse drug reactions is high,but they are all controllable.